AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23768769 — intervention group
Group type: EXPERIMENTAL
Intervention: Large defect area
Number of subjects: 865
Study 21885549 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapleural streptokinase (3 cycles of 250,000 U)
Number of subjects: 47
Study 21885549 — intervention group
Group type: COMPARATOR
Intervention: Control group (pleural drainage only)
Number of subjects: 47
Study 19345145 — intervention group
Group type: EXPERIMENTAL
Intervention: TK-cells infused starting 28 days after transplantation
Number of subjects: 50
Study 19345145 — intervention group
Group type: EXPERIMENTAL
Intervention: TK-cells infusion
Number of subjects: 50
Study 16679277 — intervention group
Group type: EXPERIMENTAL
Intervention: Gd-BOPTA
Number of subjects: 45
Study 16679277 — intervention group
Group type: COMPARATOR
Intervention: Gd-DTPA
Number of subjects: 45
Study 16679277 — intervention group
Group type: COMPARATOR
Intervention: Gd-DOTA
Number of subjects: 45
Study 15292468 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral condition
Number of subjects: 57
Study 15292468 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 57
Study 11177331 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous enoxaparin once daily (1.5 mg/kg)
Number of subjects: 900
Study 11177331 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous enoxaparin twice daily (1.0 mg/kg)
Number of subjects: 900
Study 11177331 — intervention group
Group type: COMPARATOR
Intervention: Intravenous unfractionated heparin
Number of subjects: 900
Study 11177331 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 900
Study 9541762 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacologic management of angina
Number of subjects: 558
Study 9541762 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacologic management of angina and ambulatory ECG evidence of ischemia
Number of subjects: 558
Study 9541762 — intervention group
Group type: EXPERIMENTAL
Intervention: Revascularization (angioplasty and coronary artery bypass surgery)
Number of subjects: 558
Study 9541762 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 558
Study 7889194 — intervention group
Group type: EXPERIMENTAL
Intervention: TCV-116 at 4 mg/day for 4 weeks
Number of subjects: 8
Study 7889194 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 7889194 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups during arithmetic stress
Number of subjects: 8
Study 2663263 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium aspartate (10 mmol/day) for 8 weeks
Number of subjects: 25
Study 2663263 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 4612057 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg morphine intravenously
Number of subjects: 69
Study 30815695 — intervention group
Group type: EXPERIMENTAL
Intervention: Air velocity at the feeder: 1, 2, and 3 m/s
Number of subjects: 216
Study 30815695 — intervention group
Group type: COMPARATOR
Intervention: Air velocity at the feeder: 0 m/s (control)
Number of subjects: 216
Study 28495265 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) at 5 cm of water pressure
Number of subjects: 2200
Study 28495265 — intervention group
Group type: COMPARATOR
Intervention: Control (no CPAP)
Number of subjects: 2200
Study 28495265 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP in children younger than 1 year
Number of subjects: 2200
Study 28495265 — intervention group
Group type: COMPARATOR
Intervention: Control in children younger than 1 year
Number of subjects: 2200
Study 28495265 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP in children aged up to 6 months
Number of subjects: 2200
Study 28495265 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP in children aged 12 months
Number of subjects: 2200
Study 28495265 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP in children aged 24 months
Number of subjects: 2200
Study 28495265 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP in children aged 36 months
Number of subjects: 2200
Study 28495265 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 2200
Study 28495265 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 2200
Study 25106891 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRHa therapy (1.2 mg daily as nasal spray for 4 weeks before and 4 weeks after surgery)
Number of subjects: 62
Study 25106891 — intervention group
Group type: COMPARATOR
Intervention: Orchiopexy alone
Number of subjects: 62
Study 22185951 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell salvage group
Number of subjects: 20
Study 22185951 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 22185951 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study 18272539 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus fermentum VRI-003 (PCC)
Number of subjects: 20
Study 18272539 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 18808628 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete silver yoga with stretching and meditation
Number of subjects: 204
Study 18808628 — intervention group
Group type: EXPERIMENTAL
Intervention: Shortened silver yoga without guided-imagery meditation
Number of subjects: 204
Study 18808628 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 204
Study 16100298 — intervention group
Group type: EXPERIMENTAL
Intervention: Darifenacin 15 mg
Number of subjects: 188
Study 16100298 — intervention group
Group type: EXPERIMENTAL
Intervention: Darifenacin 75 mg
Number of subjects: 188
Study 16100298 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg (positive control)
Number of subjects: 188
Study 16100298 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 188
Study 12047487 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained release paracetamol (SR paracetamol), 4 g/day (two 665 mg tablets taken three times daily)
Number of subjects: 403
Study 12047487 — intervention group
Group type: COMPARATOR
Intervention: Immediate release paracetamol (IR paracetamol), 4 g/day (two 500 mg tablets taken four times daily)
Number of subjects: 403
Study 15321150 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia
Number of subjects: 21
Study 15321150 — intervention group
Group type: COMPARATOR
Intervention: Epidural anaesthesia
Number of subjects: 21
Study 7555167 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenic drainage (AD)
Number of subjects: 10
Study 7555167 — intervention group
Group type: COMPARATOR
Intervention: Postural drainage with clapping (PD)
Number of subjects: 10
Study 2259925 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose megestrol acetate
Number of subjects: 0
Study 7032826 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg three times a day)
Number of subjects: 20
Study 7032826 — intervention group
Group type: COMPARATOR
Intervention: Captopril (200 mg three times a day) + Placebo
Number of subjects: 20
Study 31679812 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly group visits sessions (n=55)
Number of subjects: 109
Study 31679812 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n=54)
Number of subjects: 109
Study 31488369 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n=644)
Number of subjects: 1371
Study 31488369 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=727)
Number of subjects: 1371
Study 27885470 — intervention group
Group type: EXPERIMENTAL
Intervention: Transforaminal endoscopic discectomy (TED)
Number of subjects: 143
Study 27885470 — intervention group
Group type: COMPARATOR
Intervention: Microdiscectomy (Micro)
Number of subjects: 143
Study 25450709 — intervention group
Group type: EXPERIMENTAL
Intervention: Besifovir 90 mg
Number of subjects: 89
Study 25450709 — intervention group
Group type: EXPERIMENTAL
Intervention: Besifovir 150 mg
Number of subjects: 89
Study 25450709 — intervention group
Group type: COMPARATOR
Intervention: Entecavir 0.5 mg
Number of subjects: 89
Study 23337964 — intervention group
Group type: EXPERIMENTAL
Intervention: Aloe vera
Number of subjects: 40
Study 23337964 — intervention group
Group type: EXPERIMENTAL
Intervention: Chamomilla recutita
Number of subjects: 40
Study 23337964 — intervention group
Group type: EXPERIMENTAL
Intervention: Melissa officinalis
Number of subjects: 40
Study 23337964 — intervention group
Group type: EXPERIMENTAL
Intervention: Melaleuca alternifolia
Number of subjects: 40
Study 23337964 — intervention group
Group type: EXPERIMENTAL
Intervention: Coriandrum sativum
Number of subjects: 40
Study 23337964 — intervention group
Group type: COMPARATOR
Intervention: 1% hydrocortisone acetate
Number of subjects: 40
Study 23337964 — intervention group
Group type: COMPARATOR
Intervention: 0.1% betamethasone valerate
Number of subjects: 40
Study 23337964 — intervention group
Group type: COMPARATOR
Intervention: unguentum leniens
Number of subjects: 40
Study 21226966 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitated program of evidence awareness, access to tailored research evidence, critical appraisal skills development, networking and evidence summaries
Number of subjects: 28
Study 21226966 — intervention group
Group type: COMPARATOR
Intervention: Provision of evidence summaries alone
Number of subjects: 28
Study 19742332 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasogastric decompression group
Number of subjects: 108
Study 19742332 — intervention group
Group type: COMPARATOR
Intervention: Non-nasogastric decompression group
Number of subjects: 108
Study 16732214 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anaesthesia with propofol sedation and sub-Tenon's anaesthesia (lidocaine/mercaine infusion)
Number of subjects: 32
Study 16732214 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 32
Study 16945619 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet mixer (225 kcal)
Number of subjects: 8
Study 16945619 — intervention group
Group type: COMPARATOR
Intervention: Regular mixer (478 kcal)
Number of subjects: 8
Study 14674622 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography measurements of fetal biparietal diameter (BPD), abdominal circumference (AC), and femur length (FL)
Number of subjects: 710
Study 10028206 — intervention group
Group type: EXPERIMENTAL
Intervention: Group therapy for 20 weeks
Number of subjects: 40
Study 10028206 — intervention group
Group type: COMPARATOR
Intervention: Quasi-experimental control group
Number of subjects: 40
Study 9023068 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual Drug Counseling (IDC)
Number of subjects: 62
Study 9023068 — intervention group
Group type: COMPARATOR
Intervention: Cognitive sessions
Number of subjects: 62
Study 9023068 — intervention group
Group type: COMPARATOR
Intervention: Supportive Expressive psychodynamic sessions
Number of subjects: 62
Study 2054266 — intervention group
Group type: EXPERIMENTAL
Intervention: Plain paracetamol tablets 1000 mg every 6th hour
Number of subjects: 15
Study 2054266 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol slow-release tablets 2000 mg every 12th hour
Number of subjects: 15
Study 2054266 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 6666216 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg orally administered ISDN
Number of subjects: 509
Study 6666216 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 509
Study 31398634 — intervention group
Group type: EXPERIMENTAL
Intervention: Oculo-motor exercises (six sessions per week for four weeks)
Number of subjects: 30
Study 31398634 — intervention group
Group type: COMPARATOR
Intervention: Control group (daily routine exercises)
Number of subjects: 30
Study 28816293 — intervention group
Group type: EXPERIMENTAL
Intervention: 45S5 bioactive glass
Number of subjects: 18
Study 28816293 — intervention group
Group type: COMPARATOR
Intervention: Placebo (powder of zinc oxide)
Number of subjects: 18
Study 25420474 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic seizure therapy (MST)
Number of subjects: 26
Study 23337174 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg glucagon
Number of subjects: 70
Study 23337174 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 21763935 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilpivirine 25 mg once daily
Number of subjects: 680
Study 21763935 — intervention group
Group type: COMPARATOR
Intervention: Efavirenz 600 mg once daily
Number of subjects: 680
Study 21763935 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilpivirine
Number of subjects: 680
Study 21763935 — intervention group
Group type: COMPARATOR
Intervention: Efavirenz
Number of subjects: 680
Study 19247280 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition (N; n = 21)
Number of subjects: 54
Study 19247280 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition + Strength training (N+ST; n = 17)
Number of subjects: 54
Study 19247280 — intervention group
Group type: COMPARATOR
Intervention: Control (C; n = 16)
Number of subjects: 54
Study 19247280 — intervention group
Group type: EXPERIMENTAL
Intervention: All intervention groups
Number of subjects: 54
Study 16377364 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical termination (with mifepristone)
Number of subjects: 200
Study 16377364 — intervention group
Group type: COMPARATOR
Intervention: Surgical termination
Number of subjects: 200
Study 16377364 — intervention group
Group type: EXPERIMENTAL
Intervention: Both medical and surgical termination
Number of subjects: 200
Study 15257922 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperfractionated radiation therapy combined with concomitant chemotherapy
Number of subjects: 70
Study 15257922 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy only
Number of subjects: 70
Study 11571882 — intervention group
Group type: EXPERIMENTAL
Intervention: High-tech surgical treatment modalities
Number of subjects: 0
Study 11571882 — intervention group
Group type: COMPARATOR
Intervention: Placebo surgery
Number of subjects: 0
Study 9223690 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral antibiotic
Number of subjects: 0
Study 9223690 — intervention group
Group type: EXPERIMENTAL
Intervention: IM ceftriaxone
Number of subjects: 0
Study 9223690 — intervention group
Group type: COMPARATOR
Intervention: No antibiotic
Number of subjects: 0
Study 7686707 — intervention group
Group type: EXPERIMENTAL
Intervention: HT-HES (7.5% NaCl/10% hydroxyethyl starch 200.000/0.5)
Number of subjects: 37
Study 7686707 — intervention group
Group type: COMPARATOR
Intervention: HES (0.9% NaCl/10% hydroxyethyl starch 200.000/0.5)
Number of subjects: 37
Study 3639536 — intervention group
Group type: EXPERIMENTAL
Intervention: Teaching intervention based on the Brazelton Neonatal Behavioral Assessment Scale
Number of subjects: 46
Study 3639536 — intervention group
Group type: COMPARATOR
Intervention: Newborn Information Checklist about infant behavior
Number of subjects: 46
Study 3639536 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 46
Study 31597014 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg monophasic controlled-release oxycodone tablets
Number of subjects: 15
Study 31597014 — intervention group
Group type: COMPARATOR
Intervention: 10 mg oral solution oxycodone
Number of subjects: 15
Study 31597014 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release formulations (both 20 mg tablets)
Number of subjects: 15
Study 29945259 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal formulations (shampoo and solution)
Number of subjects: 120
Study 29945259 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant use of shampoo and solution
Number of subjects: 120
Study 29945259 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 28631745 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual ISNCSCI worksheets
Number of subjects: 184
Study 28631745 — intervention group
Group type: EXPERIMENTAL
Intervention: Errors in manual ISNCSCI worksheets
Number of subjects: 184
Study 28631745 — intervention group
Group type: EXPERIMENTAL
Intervention: Panel errors in ISNCSCI classification
Number of subjects: 184
Study 26228675 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate (160 mg/d)
Number of subjects: 66
Study 26228675 — intervention group
Group type: COMPARATOR
Intervention: Extended-release niacin (0.5 g/d for 3 wk, then 1 g/d)
Number of subjects: 66
Study 23698241 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy-resistance training
Number of subjects: 50
Study 23698241 — intervention group
Group type: EXPERIMENTAL
Intervention: Plyometric plus heavy-resistance training
Number of subjects: 50
Study 23698241 — intervention group
Group type: EXPERIMENTAL
Intervention: Plyometric resistance training
Number of subjects: 50
Study 21802126 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 IR 5-grass-pollen SLIT tablets (Oralair) for 2 months
Number of subjects: 633
Study 21802126 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 IR 5-grass-pollen SLIT tablets (Oralair) for 4 months
Number of subjects: 633
Study 21802126 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 633
Study 18285392 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.6 microg kg(‐1)
Number of subjects: 40
Study 18285392 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 40
Study 17138173 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mL of 4% articaine/HCl with 1:100,000 epinephrine injected into the buccal vestibule of the tooth
Number of subjects: 53
Study 17138173 — intervention group
Group type: COMPARATOR
Intervention: Palatal injection
Number of subjects: 53
Study 14650862 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux (2.5 mg once daily for 21 +/- 2 days)
Number of subjects: 656
Study 14650862 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 656
Study 14650862 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux
Number of subjects: 656
Study 14650862 — intervention group
Group type: COMPARATOR
Intervention: Fondaparinux and Placebo
Number of subjects: 656
Study 15508780 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (n = 42)
Number of subjects: 104
Study 15508780 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadoxine/pyrimethamine (n = 30)
Number of subjects: 104
Study 15508780 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (n = 32)
Number of subjects: 104
Study 15508780 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment
Number of subjects: 104
Study 15508780 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine
Number of subjects: 104
Study 10937957 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 300
Study 10937957 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 300
Study 10937957 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 8572358 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine 7.5 micrograms
Number of subjects: 36
Study 8572358 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine 15 micrograms
Number of subjects: 36
Study 8572358 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine 30 micrograms
Number of subjects: 36
Study 8572358 — intervention group
Group type: COMPARATOR
Intervention: Control (intravenous saline)
Number of subjects: 36
Study 1716334 — intervention group
Group type: EXPERIMENTAL
Intervention: ProMACE/MOPP protocol
Number of subjects: 81
Study 1716334 — intervention group
Group type: COMPARATOR
Intervention: ProMACE/MOPP
Number of subjects: 81
Study 1716334 — intervention group
Group type: COMPARATOR
Intervention: MACOP-B
Number of subjects: 81
Study 6666224 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (80 mg once daily)
Number of subjects: 22
Study 6666224 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (80 mg twice daily)
Number of subjects: 22
Study 30311214 — intervention group
Group type: EXPERIMENTAL
Intervention: LCPUFA supplementation (0.32%, 0.64%, or 0.96% of total fatty acids)
Number of subjects: 42
Study 30311214 — intervention group
Group type: EXPERIMENTAL
Intervention: LCPUFA supplementation (0.64%)
Number of subjects: 42
Study 30311214 — intervention group
Group type: EXPERIMENTAL
Intervention: LCPUFA supplementation (0.32% and 0.64%)
Number of subjects: 42
Study 30311214 — intervention group
Group type: EXPERIMENTAL
Intervention: LCPUFA groups
Number of subjects: 42
Study 30311214 — intervention group
Group type: COMPARATOR
Intervention: Control (no LCPUFA)
Number of subjects: 42
Study 29277316 — intervention group
Group type: EXPERIMENTAL
Intervention: FLEX adaptive behavioral intervention
Number of subjects: 0
Study 29277316 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 0
Study 27133722 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Navigation (FN)
Number of subjects: 40
Study 27133722 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (C)
Number of subjects: 40
Study 24893903 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive remediation (CR) integrated into a supported education program
Number of subjects: 37
Study 24893903 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive remediation (CR)
Number of subjects: 37
Study 24893903 — intervention group
Group type: COMPARATOR
Intervention: Supported education without CR
Number of subjects: 37
Study 22762958 — intervention group
Group type: EXPERIMENTAL
Intervention: Fagerström Tolerance Questionnaire for Smokeless Tobacco (FTQ‐ST)
Number of subjects: 225
Study 22762958 — intervention group
Group type: EXPERIMENTAL
Intervention: Severson Smokeless Tobacco Dependency Scale (SSTDS)
Number of subjects: 225
Study 22762958 — intervention group
Group type: EXPERIMENTAL
Intervention: Glover‐Nilsson Smokeless Tobacco Behavioral Questionnaire (GN‐STBQ)
Number of subjects: 225
Study 22762958 — intervention group
Group type: EXPERIMENTAL
Intervention: All scales (FTQ‐ST, SSTDS, GN‐STBQ)
Number of subjects: 225
Study 22762958 — intervention group
Group type: EXPERIMENTAL
Intervention: SSTDS
Number of subjects: 225
Study 22762958 — intervention group
Group type: EXPERIMENTAL
Intervention: FTQ‐ST and GN‐STBQ
Number of subjects: 225
Study 20077492 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-aminolevulinic acid (5-ALA) at a dosage of 5 mg/kg body weight administered prior to surgery
Number of subjects: 0
Study 17050563 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of 25 mg alpha(1)-antitrypsin (AAT) daily for 4 weeks
Number of subjects: 52